These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 1628135)

  • 1. No increase in relapse in patients with myeloid leukaemias receiving rhGM-CSF after allogeneic bone marrow transplantation.
    Gupta P; Tiley C; Powles R; Treleaven J; Millar J; Catalano J
    Bone Marrow Transplant; 1992 Jun; 9(6):491-3. PubMed ID: 1628135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) administration after autologous bone marrow transplantation for acute myeloblastic leukemia enhances activated killer cell function and may diminish leukemic relapse.
    Richard C; Baro J; Bello-Fernandez C; Hermida G; Calavia J; Olalla I; Alsar MJ; Loyola I; Cuadrado MA; Iriondo A
    Bone Marrow Transplant; 1995 May; 15(5):721-6. PubMed ID: 7670401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different response to recombinant human granulocyte-macrophage colony-stimulating factor in primary and secondary graft failure after bone marrow transplantation.
    Sierra J; Terol MJ; Urbano-Ispizua A; Rovira M; Marin P; Carreras E; Batlle M; Rozman C
    Exp Hematol; 1994 Jul; 22(7):566-72. PubMed ID: 8013572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant human granulocyte-macrophage colony-stimulating factor accelerates engraftment kinetics after allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia.
    Madero L; Díaz MA; Ortega JJ; Olive T; Martínez A; Badell I; Muñoz A; Gómez P
    Haematologica; 1999 Feb; 84(2):133-7. PubMed ID: 10091411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation.
    Nemunaitis J; Rosenfeld CS; Ash R; Freedman MH; Deeg HJ; Appelbaum F; Singer JW; Flomenberg N; Dalton W; Elfenbein GJ
    Bone Marrow Transplant; 1995 Jun; 15(6):949-54. PubMed ID: 7581096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis.
    Martin-Algarra S; Bishop MR; Tarantolo S; Cowles MK; Reed E; Anderson JR; Vose JM; Bierman P; Armitage JO; Kessinger A
    Exp Hematol; 1995 Dec; 23(14):1503-8. PubMed ID: 8542938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant human non-glycosylated granulocyte-macrophage colony-stimulating factor in allogeneic bone marrow transplantation: double-blind placebo-controlled phase III clinical trial.
    Hiraoka A; Masaoka T; Mizoguchi H; Asano S; Kodera Y; Kitamura K; Takaku F; Komemushi S
    Jpn J Clin Oncol; 1994 Aug; 24(4):205-11. PubMed ID: 8072199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) in serum in bone marrow transplanted patients.
    Sallerfors B; Olofsson T; Lenhoff S
    Bone Marrow Transplant; 1991 Sep; 8(3):191-5. PubMed ID: 1720339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravesical rhGM-CSF for the treatment of late onset hemorrhagic cystitis after bone marrow transplant.
    Vela-Ojeda J; Tripp-Villanueva F; Sanchez-Cortés E; Ayala-Sanchez M; García-Ruiz Esparza MA; Rosas-Cabral A; Gonzalez-Llaven J
    Bone Marrow Transplant; 1999 Dec; 24(12):1307-10. PubMed ID: 10627639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human recombinant GM-CSF in allogeneic bone marrow transplantation for leukaemia: double-blind placebo controlled trial.
    Powles R; Treleaven J; Millar J; Gordon-Smith EC; Tiley C; Findlay M; Teo C; Duncombe A; Robinson G
    Bone Marrow Transplant; 1991; 7 Suppl 2():85-6. PubMed ID: 1878735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GM-CSF therapy for delayed engraftment after autologous bone marrow transplantation.
    Brandwein JM; Nayar R; Baker MA; Sutton DM; Scott JG; Sutcliffe SB; Keating A
    Exp Hematol; 1991 Mar; 19(3):191-5. PubMed ID: 1995310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant human glycosylated granulocyte colony-stimulating factor (rhG-CSF)-combined regimen for allogeneic bone marrow transplantation in refractory acute myeloid leukemia.
    Takahashi S; Okamoto SI; Shirafuji N; Ikebuchi K; Tani K; Shimane M; Matsudaira T; Irie S; Tsuruta T; Matsuishi E
    Bone Marrow Transplant; 1994 Mar; 13(3):239-45. PubMed ID: 7515298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant human granulocyte colony-stimulating factor after allogeneic bone marrow transplantation.
    Huang X; Guo N; Fan Y; Lu D
    Chin Med J (Engl); 1996 Nov; 109(11):827-31. PubMed ID: 9275365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of granulocyte-macrophage colony-stimulating factor and erythropoietin in combination after autologous marrow transplantation.
    Pene R; Appelbaum FR; Fisher L; Lilleby K; Nemunaitis J; Storb R; Buckner CD
    Bone Marrow Transplant; 1993 Mar; 11(3):219-22. PubMed ID: 8467286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymerase chain reaction is highly predictive of relapse in patients following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukemia.
    Mackinnon S; Barnett L; Heller G
    Bone Marrow Transplant; 1996 Apr; 17(4):643-7. PubMed ID: 8722369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged administration of recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) after T-cell-depleted allogeneic bone marrow transplantation.
    De Witte T; Vreugdenhil G; Schattenberg A
    Transplant Proc; 1993 Aug; 25(4 Suppl 3):57-60. PubMed ID: 8351721
    [No Abstract]   [Full Text] [Related]  

  • 17. Interleukin-3 followed by GM-CSF for delayed engraftment after autologous bone marrow transplantation.
    Crump M; Couture F; Kovacs M; Saragosa R; McCrae J; Brandwein J; Huebsch L; Beauregard-Zollinger L; Keating A
    Exp Hematol; 1993 Mar; 21(3):405-410. PubMed ID: 8440338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Administration of recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation in children with acute myelogenous leukemia: a note of caution.
    Calderwood S; Doyle JJ; Hitzler JK; Saunders EF; Freedman MH
    Bone Marrow Transplant; 1996 Jul; 18(1):87-91. PubMed ID: 8832000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of exogenous recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor on neutrophil function following allogeneic bone marrow transplantation.
    Fabian I; Kletter Y; Bleiberg I; Gadish M; Naparsteck E; Slavin S
    Exp Hematol; 1991 Oct; 19(9):868-73. PubMed ID: 1716591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of recombinant human granulocyte colony-stimulating factor in children given allogeneic bone marrow transplantation for acute or chronic leukemia.
    Locatelli F; Pession A; Zecca M; Bonetti F; Prete L; Carrà AM; Prete A; Montagna D; Comoli P; Taibi RM; Paolucci G
    Bone Marrow Transplant; 1996 Jan; 17(1):31-7. PubMed ID: 8673051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.